111051-32-2

Basic information

• Product Name: (-)-Bamethan
• Synonyms: bamethane;Benzenemethanol, α-[(butylamino)methyl]-4-hydroxy-, (-)-
• CAS NO: 111051-32-2
• Molecular Formula: C₁₂H₁₉NO₂
• Molecular Weight: 209.28
• Mol File: 111051-32-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 375.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.079±0.06 g/cm3(Predicted)
• PKA: 9.97±0.26(Predicted)
• CAS DataBase Reference: (-)-Bamethan(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-Bamethan(111051-32-2)
• EPA Substance Registry System: (-)-Bamethan(111051-32-2)

Safety Data

• Hazardous Substances Data: 111051-32-2(Hazardous Substances Data)

Usage

General Description

(-)-Bamethan is a chemical compound that belongs to the class of adrenergic beta-agonists, which are commonly used as bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It acts by stimulating beta-2 adrenergic receptors in the smooth muscle of the airways, leading to relaxation and dilation of the bronchial passages. This results in improved airflow and relief from symptoms such as wheezing, shortness of breath, and chest tightness. (-)-Bamethan is characterized by its ability to selectively target beta-2 receptors, thereby minimizing unwanted side effects associated with the stimulation of other adrenergic receptors. It is considered an effective and well-tolerated bronchodilator, making it a valuable option for managing respiratory conditions.

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 6388-72-3 2-(4-methoxyphenyl)oxirane 
• 18986-11-3 2-butylamino-1-(4-hydroxy-phenyl)-ethanone 
• 5324-15-2 4'-benzoyloxy-2-bromoacetophenone 

Downstream Products

• 132034-25-4 N-Butyl-C-((S)-7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-yl)-N-[2-hydroxy-2-(4-hydroxy-phenyl)-ethyl]-methanesulfonamide 
• 7339-87-9 4-hydroxyphenylacetaldehyde 

Relevant articles and documents

BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic steatohepatitis (NASH), wherein X, R1, R2, R3 and n have meanings as provided in the description.

Pharmaceutical formula

The present invention concerns a pharmacological vehicle or carrier system, which makes possible administration of the active ingredient with a high absorption thereof in the blood circulation of the patient treated therewith, in particular also in the case of oral administration. The pharmacological vehicle system according to the invention comprises ultrafine particles of a reaction product of a reactive derivative of an at least dibasic inorganic acid or an alkane-carboxylic acid having 2 or 3 carboxyl groups and optionally one or two hydroxy groups, wherein one bond of the dibasic inorganic acid or one carboxy group of the alkane-carboxylic acid is bonded to a pharmacological active ingredient containing a hydroxy group, SH group and/or a primary or secondary amino group having a ractive hydrogen atom on this group, and the other bond is bonded to the free hydroxy group of a glycerolipid having at least one free hydroxy group on the glycerol. The invention further concerns these reaction products and a process for the preparation of ultrafine particles of these reaction products.